BioCardia (BCDA)

• Market cap: $12.4M
• 1 day: -5.73%
• 5 days: 4.9%
• 1 month: 22.99%
• 3 months: -2.73%
• 6 months: -16.08%
• Year to date: -5.31%
• 1 year: -24.38%
• 5 years: -93.95%
• 10 years: -97.15%
• Sector: Healthcare
• Industry: Biotechnology

About: BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Employees: 17

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33% more funds holding

Funds holding: 12 [Q1] → 16 (+4) [Q2]

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0.63% more ownership

Funds ownership: 5.24% [Q1] → 5.88% (+0.63%) [Q2]

5% less capital invested

Capital invested by funds: $624K [Q1] → $593K (-$30.5K) [Q2]